Cargando…
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and F...
Autores principales: | Wang, Ling, Devillier, Raynier, Wan, Ming, Decroocq, Justine, Tian, Liang, Fürst, Sabine, Wang, Li-Ning, Vey, Norbert, Fan, Xing, Blaise, Didier, Hu, Jiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462832/ https://www.ncbi.nlm.nih.gov/pubmed/30082853 http://dx.doi.org/10.1038/s41409-018-0283-5 |
Ejemplares similares
-
The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience
por: Blaise, Didier, et al.
Publicado: (2021) -
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
por: Koenig, Kristin, et al.
Publicado: (2020) -
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023) -
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018) -
Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen
por: Toyama, Daisuke, et al.
Publicado: (2020)